<scp>iGlarLixi</scp> versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The <scp>SoliComplex</scp> real‐world study

Abstract

In this observational study in people with T2D suboptimally controlled on basal insulin, once-daily iGlarLixi was an effective treatment alternative to premixed insulin with significantly higher treatment persistence, similar adherence and HbA1c reduction, and numerically lower hypoglycaemia events, HRU and costs, regardless of age or baseline HbA1c.